Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

November 28, 2023

https://www.globenewswire.com/news-release/2023/11/28/2786786/0/en/Alector-to-Host-Two-Virtual-Research-and-Development-Events-Highlighting-TREM2-and-Progranulin-Programs.html

SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs. The events will include presentations from Alector’s management as well as leading scientific and clinical experts who will provide their perspectives on the biological and genetic rationale for the TREM2 and PGRN targets, share an overview of the current treatment landscapes for frontotemporal dementia and Alzheimer’s disease, and discuss the significant unmet needs that remain in the treatment of these neurodegenerative diseases.

Read more at globenewswire.com

Related news for (ALEC)

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

November 28, 2023

https://www.globenewswire.com/news-release/2023/11/28/2786786/0/en/Alector-to-Host-Two-Virtual-Research-and-Development-Events-Highlighting-TREM2-and-Progranulin-Programs.html

SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs. The events will include presentations from Alector’s management as well as leading scientific and clinical experts who will provide their perspectives on the biological and genetic rationale for the TREM2 and PGRN targets, share an overview of the current treatment landscapes for frontotemporal dementia and Alzheimer’s disease, and discuss the significant unmet needs that remain in the treatment of these neurodegenerative diseases.

Read more at globenewswire.com

Related news for (ALEC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.